Related Experiment Video
Updated: May 24, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel
Young-Min Son1, Joo-Young Roh, Eun-Kyung Cho
1Department of Dermatology, Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea.
Abstract:
Vandetanib (ZD6474, Zactima™) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QC interval prolongation, and hypertension. In a few randomized, double-blinded studies, cutaneous adverse events including these general symptoms have been reported, but there are only a few reports on the photosensitivity reaction to vandetanib domestically as conducted by dermatologists. In this report, we describe two cases of photosensitivity reactions induced by vandetanib. After improvement with steroid and antihistamine, the photosensitivity reaction was redeveloped by sequential treatment with docetaxel.
Insights
Vandetanib, an anti-cancer drug, can cause photosensitivity reactions. These reactions may reappear even after initial treatment with steroids and antihistamines.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Vandetanib is an oral multi-kinase inhibitor targeting pathways crucial for tumor growth, angiogenesis, and metastasis.
- Common adverse events include diarrhea, liver enzyme elevation, QT prolongation, and hypertension.
- Cutaneous adverse events are noted, but photosensitivity reactions are infrequently reported.
Observation:
- This report details two cases of photosensitivity reactions to vandetanib.
- Patients experienced photosensitivity following vandetanib treatment.
- Reactions recurred upon subsequent docetaxel therapy after initial improvement with steroids and antihistamines.
Findings:
- Vandetanib can induce photosensitivity reactions.
- Photosensitivity reactions may be severe enough to warrant discontinuation or management.
- The photosensitivity reaction can recur with subsequent treatments, even after initial management.
Implications:
- Dermatologists should be aware of photosensitivity as a potential adverse event of vandetanib.
- Early recognition and management of photosensitivity are crucial for patient care.
- Further investigation into the mechanisms and management of vandetanib-induced photosensitivity is warranted.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:30Drug Toxicity: Allergic Reactions